Our technology can save lives with early cancer detection
Cancer is one of the most common causes of death in the US, second only to cardiovascular diseases. Multi-cancer early detection is on the cutting edge of cancer research, promising to reduce cancer deaths by 40%.
Non-invasive multi-cancer early detection
miRoncol is developing a novel test, using well-established technology and infrastructure, that can detect multiple types of cancer in their early stages.
Compared to other multi-cancer early detection technologies, miRoncol's unique test demonstrates superior performance with high sensitivity and specificity.
miRoncol provides a low-cost solution to cancer screening using an RT-PCR based assay of limited number of microRNAs.
miRoncol's test requires only a small blood sample, one that can be readily tested in any diagnostic lab across the US.
types of cancer are currently supported, with more on the way.
Specificity, i.e. <1% of non-cancer samples would be tested as positive.
Sensitivity, i.e. ~90% of actual cancer cases can be detected.
blood samples used for model development and validation.
Poster presentation at the 2022 Annual Meeting of American Association for Cancer Research.